Publication date: Available online 17 September 2026 Source: Journal of Thoracic Oncology Author(s): Todd M. Bauer, Jean-François Martini, Benjamin Besse, Chia-Chi Lin, Ross A. Soo, Gregory J. Riely, I-Ming Wang, Francesca Toffalorio, Deborah A. Shepard, Tiziana Usari, Phineas Hamilton, D. Ross Camidge, Steven Kao, Rita Chiari, Shirish Gadgeel, Enriqueta Felip, Alice T. Shaw, Benjamin J. Solomon
Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced NSCLC in a Phase 2 Study. // Journal of Thoracic Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1556086426006556?dgcid=rss_sd_all
Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced NSCLC in a Phase 2 Study. Journal of Thoracic Oncology. https://www.sciencedirect.com/science/article/pii/S1556086426006556?dgcid=rss_sd_all
“Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced NSCLC in a Phase 2 Study.” Journal of Thoracic Oncology.
@article{article108093,
title = {Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced NSCLC in a Phase 2 Study},
journal = {Journal of Thoracic Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1556086426006556?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment